Sina Medicine Live Lesson 7 New Coronavirus Vaccine (Adenovirus Vector) Research Progress.

In recent years, pharmaceutical industry policies have been introduced, consistent evaluation, China's accession to ICH, MAH implementation, drug clinical trial data verification and other accelerated industry survival of the fittest;
the reform of medical policy, the development of China's pharmaceutical industry is entering the fast track of norms.
the context of the rise of "healthy China" as a national strategy, China is undergoing a transformation from a "medical power" to a "medical power".
biopharmaceutical industry, as one of china's seven strategic emerging industries, is becoming a new engine of China's economic development.
through policy regulation, investment of supporting resources and improvement of institutional mechanism construction, China's biopharmaceutical industry has transitioned from "technological backwardness" to "following the international pace", in which the development of innovative drugs is particularly rapid.
has also emerged a number of innovative biopharmaceutical companies, such as Baiji Shenzhou, Xinda Bio, Consino Bio, and independent research and development of innovative drugs were approved for market.
to sustain rapid growth, more top talent will be needed and the overall level of employees will be improved.
In order to provide innovative pharmaceutical practitioners with a free and smooth exchange platform, Sina Pharmaceuticals has launched a "New Zhihui" online live knowledge sharing platform, which will focus on hot topics such as target discovery, new technology development and application, process development and verification, drug clinical trial design, and so on, through strategy and case sharing, directly hit the confusion in research and development production.
Monday, October 19th, the 7th lesson of "New Zhihui" weighs in, and Mr. Li Junqiang, Senior Director of Consino Bio AG, will share with you "the progress of research on the new coronavirus vaccine (adenovirus vector)" and look forward to your participation.
Share theme: New coronavirus vaccine (adenovirus vector) research progress 1, all aspects of the adenovirus vector new coronavirus vaccine research overview; October 19, 2000 19:30-20:30 Mr. Li Junqiang, Senior Director of Concino Biological AG, Lanzhou University, Bachelor of Biology, Lanzhou Institute of Biological Products, Master of Immunology, has worked in Concord Stem Cells, Tianshili Biology, United Sayer, etc., joined Concino Bio-AG in 2014, is currently senior director.
has more than ten years of experience in vaccine development and can solve all kinds of technical problems in vaccine research and development, especially in preparation research and pharmacological research.
in Consino as project leader for the new recombinant TB vaccine, the 100-part white-break vaccine and the combined vaccine.
's new recombinated TB vaccine, the world's innovative Cajun-Enhanced Immune Candidate Vaccine, has completed Phase Ia clinical trials in Canada and is undergoing Phase I Clinical Trials;
In addition, Li Junqiang also participated as the technical backbone of the adenovirus vector coronavirus vaccine, adenovirus vector Ebola vaccine, recombinant pneumococcal protein vaccine, 13-price pneumococcal binding vaccine and other projects, successfully completed the vaccine preparation research, pharmacoephase research and other tasks.
Li Junqiang led the early research and development department to complete the development of a number of new antigens, new vectors, completed a number of innovative vaccine early research work, a number of invention patents are about to be granted.
: This course is free and open, scan the QR code below to add Sina Medicine Live Assistant, register.
(Note: Name and Company)